GlassScriptPhysician profile
Lindsey T Corbett
NPI 1154921641
$1,897.91
in general payments reported to CMS, 2019-2025
21 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $464 · 2023: $482 · 2024: $180 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $392.24 | 2022-2025 | Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $318.41 | 2021-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $302.55 | 2021-2023 | Veltassa |
| Calliditas Therapeutics US INC. | $208.96 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $117.04 | 2021 | |
| Fresenius USA Marketing, INC. | $64.35 | 2021-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $63.44 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $63.23 | 2021-2025 | Jynarque, Rexulti |
| Daiichi Sankyo INC. | $54.14 | 2021-2023 | Injectafer |
| Glaxosmithkline, LLC. | $49.90 | 2023-2024 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $47.97 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $47.13 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $44.73 | 2021-2023 | Acthar |
| Baxter Healthcare | $21.70 | 2024 | Renal - Chronic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.61 | 2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.67 | 2024 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $15.28 | 2025 | |
| Lilly USA, LLC | $13.94 | 2023 | Jardiance |
| Amgen INC. | $13.48 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.46 | 2021 | |
| Travere Therapeutics, INC. | $10.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.